Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment

Abstract

In vivo modeling combined with CRISPR/Cas9-mediated somatic genome editing has contributed to elucidating the functional importance of specific genetic alterations in human tumors. Our recent work uncovered tumor suppressor pathways that affect EGFR-driven lung tumor growth and sensitivity to tyrosine kinase inhibitors and reflect the mutational landscape and treatment outcomes in the human disease.

Keywords

• lung cancer
• egfr
• targeted therapy
• tumor suppressor genes
• multiplexed in vivo genome editing